Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil
Milestone’s NDA for CARDAMYST is currently under review at the FDA with a Prescription Drug User Fee Act (PDUFA) target date of March 27, 2025. The Company continues to advance commercial preparations ...
Milestone receives notice of allawance from USPTO on etripamil nasal spray
Milestone Pharmaceuticals (MIST) announced that it has received Notice of Allowance from the United States Patent and Trademark Office, or ...
Live Law50m
Right To Be Forgotten By Destroying Records Of Juvenile Delinquency Is Absolute, Has To Be Given Full Meaning By The State: Rajasthan HC
For the welfare of a child, the burden of past mistakes must be lifted, offering him a fresh start to thrive, free from the weight of stigma…shadows of past transgressions should be expunged...” ...